Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined the dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations. DTG dissociates slowly from a wild-type IN-DNA complex at 37°C with an off-rate of 2.7 × 10 −6 s −1 and a dissociative half-life ( t 1/2 ) of 71 h, significantly longer than the half-lives for RAL (8.8 h) and ELV (2.7 h). Prolonged binding ( t 1/2 , at least 5 h) was observed for DTG with IN-DNA complexes containing E92, Y143, Q148, and N155 substitutions. The addition of a second substitution to either Q148 or N155 typically resulted in an increase in the off-rate compared to that with the single substitution. For all of the IN substitutions tested, the off-rate of DTG from IN-DNA complexes was significantly slower (from 5 to 40 times slower) than the off-rate of RAL or ELV. These data are consistent with the potential for DTG to have a higher genetic barrier to resistance, provide evidence that the INI off-rate may be an important component of the mechanism of INI resistance, and suggest that the slow dissociation of DTG may contribute to its distinctive resistance profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the dissociation half-times of dolutegravir and bictegravir from the wild-type HIV-1 intasome were reported to be ~100 and 160 h, respectively164,165.”
From Structure and function of retroviral integrase (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complete nucleotide sequence of the AIDS virus, HTLV-III
Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., et al. (1985) · Nature · doi:10.1038/313277a0 · Cited by 2,245
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Since INI binding generates nonreplicative forms of unintegrated viral cDNA, such as 2 long terminal repeats (27), there is less opportunity for the virus to undergo further rounds of replication which can generate additional mutations and thereby VOL.”
BackgroundRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Markowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Self-citationShimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010246107 · Cited by 305 · cited 1×
“The crystal structures of prototype foamy virus (PFV) IN in complex with DNA and RAL, ELV, (24), or DTG (25) and HIV-1 IN structural modeling studies (8, 9) provide insight into INI binding modes and how substitutions in the active site could impact INI binding.”
Background
Research works printed but not linked: 9
- DeAndaF. HattoriK. YoshinagaT. KawasujiT. UnderwoodM. R.. 2010. Structural models of HIV-1 integrase and DNA in complex with S/GSK1349572, raltegravir, or elvitegravir: structure-based rationale for INI resistance profiles. Antiviral Ther. 15(Suppl. 2):A73.
- DeAndaF. . 2010. Structural rationale for slow S/GSK1349572 dissociation from wild type (WT) and raltegravir (RAL) resistant HIV-1 integrase (IN), abstr. H-1166. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
- DeJesusE. . 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137), abstr. TUPEB032. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention. International AIDS Society, Geneva, Switzerland.
- DickerI. B. . 2011. Longer integrase inhibitor dissociation half-lives induce persistent anti-HIV effects in cell culture, abstr. 521. Abstr. 18th Conf. Retrovir. Opportunistic Infect.
- GroblerJ. A. . 2009. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors, abstr. O-10. Abstr. 10th Int. Workshop Clin. Pharmacol. HIV Ther.
- HluhanichR. . 2010. HIV integrase inhibitors (INIs) do not exert a post-antibiotic effect (PAE) despite slow dissociation from IN-DNA complexes in vitro, abstr. H-930. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
- JohnsB. . 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile, abstr. 55. Abstr. 17th Conf. Retrovir. Opportunistic Infect.
- UnderwoodM. R. JohnsB. SatoA. FujiwaraT. SpreenW.. 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, abstr. WEPEA098. Abstr. 5th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention. International AIDS Society, Geneva, Switzerland.
- YoshinagaT. Kanamori-KoyamaM. SekiT. SatoA. FujiwaraT.. 2010. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Antivir. Ther. 15(Suppl. 2):A12.
Cited by
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Self-citationHoffmann, C., Welz, T., Sabranski, M., Kolb, M. R. J., Wolf, E., Stellbrink, H., & Wyen, C. (2016) · HIV Medicine · doi:10.1111/hiv.12468 · Cited by 316
van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70290-0 · Cited by 301
Cottrell, M. L., Hadzic, T., & Kashuba, A. D. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0093-2 · Cited by 298
Metadata
- Authors
- Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R.
- Affiliations
- GlaxoSmithKline, Research Triangle Park, North Carolina
- Shionogi (Japan) (JP)
- Corresponding author
- Underwood, Mark R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-10
- Volume
- 55
- Issue
- 10
- Pages
- 4552-4559
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3187001
- OpenAlex
- W2144255757
- Cited by
- 226
- References
- 39
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 11 · 2017: 19 · 2016: 16 · 2015: 32 · 2014: 27 · 2013: 23 · 2012: 17
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- dolutegravir, raltegravir, elvitegravir, HIV-1 integrase inhibitors, integrase inhibitor resistance, integrase-DNA complex, dissociation rate, dissociation rate constant, resistance mutations, resistance mechanisms
- MeSH terms
- Raltegravir Potassium, Dolutegravir, DNA, Viral, Genotype, Heterocyclic Compounds, 3-Ring, Mutation, Oxazines, Piperazines, Pyridones, Pyrrolidinones, Quinolones, HIV-1, DNA, Complementary, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes. https://app.cochat.ai/papers/10.1128/aac.00157-11
- The paper
- Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R. (2011). Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00157-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.